Abstract
Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes
Volume: 13 Issue: 2
Author(s): Wilbert S. Aronow
Affiliation:
Keywords: Acute coronary syndromes, unstable angina pectoris, non-ST-elevation myocardial infarction, aspirin, clopidogrel, prasugrel, ticagrelor, glycoprotein IIb/IIIa inhibitors, cangrelor, voraxapar.
Abstract: Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article.
If ticagrelor is used, the dose of aspirin must not exceed 100 mg daily. Prasugrel must not be used in patients with a history of stroke or transient ischemic attack. Platelet glycoprotein IIb/IIIa inhibitors should not be used as part of triple antiplatelet drug therapy if there is an increased risk for bleeding or in non-high-risk patients such as those with a normal baseline cardiac troponin level, nondiabetics, and those aged 75 years and older in whom potential benefit may be significantly offset by the potential risk of bleeding. Clinical trial data in patients with acute coronary syndromes do not support the use of intravenous cangrelor or oral voraxapar in the treatment of these patients.
Export Options
About this article
Cite this article as:
Aronow S. Wilbert, Use of Antiplatelet Drugs in the Treatment of Acute Coronary Syndromes, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/1871529X11313020008
DOI https://dx.doi.org/10.2174/1871529X11313020008 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Translational Imaging of Apoptosis
Anti-Cancer Agents in Medicinal Chemistry The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Human Tissue Kallikrein: A New Bullet for the Treatment of Ischemia
Current Pharmaceutical Design Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Current Pharmaceutical Design L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Endothelial Progenitors in Vascular Repair and Angiogenesis: How Many are Needed and What to do?
Cardiovascular & Hematological Disorders-Drug Targets Circulating Biomarkers Determining Inflammation in Atherosclerosis Progression
Current Medicinal Chemistry Triiodothyronine (T3) Effects on Cardiovascular System in Patients with Heart Failure
Recent Patents on Cardiovascular Drug Discovery MicroRNAs: An Apparent Switch for High-Altitude Pulmonary Edema
MicroRNA Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine
Mini-Reviews in Medicinal Chemistry Predictive Value of Methods Measuring Platelet Activation for Ischemic Events in Patients Receiving Clopidogrel: A Systematic Review and Meta-analysis
Current Pharmaceutical Design Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Cardiovascular and Renal Complications of Type 2 Diabetes in Obesity:Role of Sympathetic Nerve Activity and Insulin Resistance
Current Diabetes Reviews The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design How to Keep Oxidative Stress Under Control?
Current Nutrition & Food Science Glycogen Phosphorylase Inhibitors
Mini-Reviews in Medicinal Chemistry Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets High Serum Alkaline Phosphatase Levels in Relation to Multi-Cerebral Microbleeds in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare
Reviews on Recent Clinical Trials